PRESS RELEASE
Lyon, July 25, 2025




ADOCIA and Tonghua Dongbao Announce
Positive Topline Results of Phase 3 Clinical Trial on
Ultra-Rapid Insulin BioChaperone® Lispro
(THDB0206 injection) in people with T2D

• This Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection) conducted in
China in people with Type 2 diabetes, successfully demonstrated, in comparison with
standard of care Humalog®:
o Non inferior HbA1c reduction at 26 weeks (primary endpoint)
o Significant reduction of the rise of blood glucose after a test meal (key secondary
endpoints)
• Mean blood glucose level over the day monitored by 10-point SMBG, an important
supportive endpoint, was also significantly decreased, in comparison with Humalog®
• A series of prespecified subgroup analyses in HbA1c fully support the benefit of the product
in long term blood glucose control


8:45 am CEST - Adocia (Euronext Paris: FR0011184241 – ADOC, the “Company”), a clinical-stage
biopharmaceutical company focused on the research and development of innovative therapeutic solutions for
the treatment of diabetes and obesity, announces that its partner Tonghua Dongbao releases today positive
topline results on the Phase 3 clinical trial on BioChaperone® Lispro (THDB0206 injection), a novel Ultra-Rapid
Insulin formulation.

Conducted by Tonghua Dongbao, this Phase 3 study (NCT05834868) was approved by the Chinese Regulatory
Authorities (CDE1). The randomized, open, multicenter study evaluated the safety and efficacy of THDB0206
injection compared to Humalog® in adults with Type 2 diabetes.




1
CDE: Center for Drug Evaluation of the National Medical Products Administration


1
Dr LENG Chunsheng, President of Tonghua Dongbao, said: "THDB0206 injection is a new generation of ultra-rapid
insulin that has demonstrated benefits for improving blood glucose control of adults with Type 2 diabetes compared
with the standard of care Humalog®. Tonghua Dongbao is committed to continue to innovate in the treatment of
diabetes and obesity."

Olivier Soula, CEO and Co-Founder of Adocia, added: "We are thrilled to share the positive results obtained with
BioChaperone® Lispro on this Phase 3 clinical trial on people with Type 2 diabetes. Given the well-known challenges in
showing clinical improvement in this population with a new prandial insulin, we are particularly delighted with these
findings. This milestone demonstrates Adocia’s ability to advance its innovative treatments to the final stages of clinical
development, within strategic partnerships. We congratulate Tonghua Dongbao’s team for the quality of execution of
a large Phase 3 trial of over 1,000 people.”




Results
A total of 1,040 Chinese adults with Type 2 diabetes with inadequate glycemic control and using daily multiple
injections of insulin were randomized.

After 26 weeks of treatment, HbA1c decreased significantly in both groups compared to the baseline. The
reduction in the THDB0206 injection group was comparable to that of the Humalog® group, meeting the
primary endpoint.

The key secondary endpoints were also demonstrated, with a statistically significant lower rise of blood glucose
after a standard meal for the THDB0206 injection group, compared to the Humalog® group.

The 10-point self-monitoring blood glucose (SMBG) of patients at week 26, an important supportive endpoint
of the trial, confirmed the advantage of this product in controlling postprandial blood glucose fluctuations, with
a statistically improved daily blood glucose level. A series of prespecified subgroup analyzes of the primary
HbA1c endpoint also fully confirmed the benefits of this product in long-term blood glucose control in patients
with Type 2 diabetes.

In addition, the safety and tolerability of THDB0206 injection were good. Most of the adverse events were mild
or moderate, and the incidence of adverse events and hypoglycemic events were similar to those of Humalog®.




About BioChaperone® Lispro
BioChaperone® Lispro was licensed to Tonghua Dongbao in 2018, as part of a Licensing Agreement covering
China and other Asian countries2.

BioChaperone® Lispro is an Ultra-Rapid Insulin, belonging to the latest generation of prandial insulins. It
combines Adocia's proprietary BioChaperone® technology with insulin lispro, the active ingredient in the
standard of care, Humalog® (Eli Lilly).

This innovative formulation acts significantly faster than earlier insulin generations, effectively reducing post-
meal hyperglycemia, which is a key contributor to long-term complications such as retinopathy, diabetic foot




2
Press Release, Apr. 26, 2018: Adocia and Tonghua Dongbao Announce a Strategic Alliance for BioChaperone ® Combo and BioChaperone® Lispro
in China


2
ulcers, or kidney failure. Additionally, its rapid elimination minimizes the risk of hypoglycemia, often caused when
insulin level remains high after post-meal glucose levels have normalized.

The faster action profile of BioChaperone® Lispro associated to an excellent local tolerance enhances its
compatibility with modern diabetes management systems, particularly insulin pump systems, and provides better
integration into advanced treatment algorithms.

Beyond its clinical advantages, the quick onset of BioChaperone ® Lispro improves quality of life by offering
greater flexibility in dose timing. Patients can administer insulin at mealtime, or even right-after-mealtime,
allowing for more accurate dosing based on known meal timing and content. This reduces the risks of overdosing
or underdosing, which can lead to hypo- or hyperglycemia and their associated complications. The simplified
dosing process eases the psychological burden on patients and caregivers, significantly alleviating the stress
associated with diabetes management.




About Tonghua Dongbao
Tonghua Dongbao Pharmaceutical Co. Ltd (SHSE: 600867), is a pharmaceutical company based in Jilin province,
China, specializing in the R&D, manufacturing and commercialization of insulins and other diabetes treatments.
Tonghua Dongbao currently employs over 3,000 people and has sales of around $280 million. It has been listed
on the Shanghai Stock Exchange since 1994, with a market capitalization of about $2.3 billion.




About Adocia
Adocia is a biotechnology company specializing in the discovery and development of therapeutic solutions in the
field of metabolic diseases, primarily diabetes and obesity.

The Company has a broad portfolio of drug candidates based on four proprietary technology platforms: 1) The
BioChaperone® technology for the development of new generation insulins and products combining different
hormones; 2) AdOral®, an oral peptide delivery technology; 3) AdoShell ®, an immunoprotective biomaterial for
cell transplantation, with an initial application in pancreatic cells transplantation; and 4) AdoGel ®, a long-acting
drug delivery platform.

Adocia holds more than 25 patent families. Based in Lyon, the company has about 80 employees. Adocia is listed
on the regulated market of Euronext™ Paris (Euronext: ADOC; ISIN: FR0011184241).




3
Contact
Adocia Ulysse Communication
Olivier Soula Adocia Press & Investor Relations
CEO Bruno Arabian
Nicolas Entz
contactinvestisseurs@adocia.com
adocia@ulysse-communication.com
+33 (0)4 72 610 610
+ 33 (0)6 87 88 47 26
www.adocia.com




Disclaimer
This press release contains certain forward-looking statements analyses and the evolution of economic conditions, the financial
concerning Adocia and its business. Such forward-looking statements markets and the markets in which Adocia operates, which could
are based on assumptions that Adocia considers as being reasonable. impact the Company's short-term financing requirements and its
However, there can be no guarantee that the estimates contained in ability to raise additional funds.
such forward-looking statements will be achieved, as such estimates The forward-looking statements contained in this press release
are subject to numerous risks including those set forth in the “Risk are also subject to risks not yet known to Adocia or not considered
Factors” section of the universal registration document that was filed as material by Adocia at this time. The occurrence of all or part of
with the French Autorité des marchés financiers on April 29, 2025, such risks could cause the actual results, financial conditions,
available at www.adocia.com. Those risks include uncertainties performances, or achievements of Adocia be materially different
inherent in Adocia's short- or medium-term working capital from those mentioned in the forward-looking statements.
requirements, in research and development, future clinical data,




4